Research programme: heat shock protein modulators - Reata Pharmaceuticals

Drug Profile

Research programme: heat shock protein modulators - Reata Pharmaceuticals

Latest Information Update: 18 Jan 2017

Price : $50

At a glance

  • Originator University of Kansas
  • Developer Reata Pharmaceuticals
  • Class Small molecules
  • Mechanism of Action HSP70 heat-shock protein modulators; HSP90 heat-shock protein inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

  • New Molecular Entity Yes

Highest Development Phases

  • Preclinical Diabetic neuropathies
  • Research Alzheimer's disease; Demyelinating disorders

Most Recent Events

  • 12 Feb 2016 Reata Pharmaceuticals plans a phase-I trial in healthy volunteers in USA (PO; Capsule) (NCT02666963)
  • 12 Oct 2015 Early research in Alzheimer's disease in USA (unspecified route)
  • 12 Oct 2015 Early research in Demyelinating disorders in USA (unspecified route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top